

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

COMP/M.4367 - APW / APSA / NORDIC CAPITAL / CAPIO

SECTION 1.2

Description of the concentration

The Commission has received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (the "Regulation") under which Apax Partners Worldwide LLP ("APW"), Apax Partners SA ("APSA") and Nordic Capital Fund VI ("Nordic Capital"; together referred to as the "Parties") via the acquisition vehicle Opica AB ("Opica") intend to acquire within the meaning of Article 3(1)(b) of the Regulation joint control over Capio AB (publ) and its affiliates ("Capio").

The business activities of the undertakings concerned are as follows:

- APW: private equity investments;
- APSA: private equity investments;
- Nordic Capital: private equity investments; and
- Capio: provider of private healthcare (including hospitals and diagnostic services) in the UK, Sweden, Norway, Denmark, Finland, France, Spain and Germany.

The proposed concentration results in one horizontally affected market in the UK between Capio and APW's Portfolio company General Healthcare Group in relation to the operation of private acute general hospitals in the UK and in several vertically affected markets relating to the supply of medical supplies and/or pharmaceutical products, between Capio and APW's Mölnlycke Healthcare and Nordic Capital's Nycomed, Unomedical and Atos Medical.